ARS Pharmaceuticals, Inc. — Director's Dealing 2025

Aug 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-08-21

Reporting Person: Scott Kathleen D. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-21	Common Stock	M	12500	$1.50	Acquired	22542	Direct
2025-08-21	Common Stock	S	12500	$15	Disposed	10042	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-21	Stock Option (Right to Buy)	$1.50	M	12500	Disposed	2032-02-29	Common Stock (12500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8250	Indirect

Footnotes

F1: Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.

F2: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025.

F3: Immediately exercisable.